Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02038036
Title Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (RESPONSE-2)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: senior | adult
Covered Countries ITA | FRA | ESP | DEU | CAN | BEL | AUS

Facility Status City State Zip Country Details
Novartis Investigative Site Herston Queensland 4029 Australia Details
Novartis Investigative Site Antwerpen 2060 Belgium Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Toronto Ontario M4N 3M5 Canada Details
Novartis Investigative Site Bayonne Bayonne Cedex 64109 France Details
Novartis Investigative Site Bordeaux 33076 France Details
Novartis Investigative Site Brest 29200 France Details
Novartis Investigative Site Lille cedex 59020 France Details
Novartis Investigative Site Nice Cedex 06202 France Details
Novartis Investigative Site Paris 75010 France Details
Novartis Investigative Site Toulouse 31059 France Details
Novartis Investigative Site Mannheim Baden-Wuerttemberg 68305 Germany Details
Novartis Investigative Site Augsburg 86150 Germany Details
Novartis Investigative Site Dresden 01307 Germany Details
Novartis Investigative Site Jena 07740 Germany Details
Novartis Investigative Site Leipzig 04103 Germany Details
Novartis Investigative Site Magdeburg 39120 Germany Details
Novartis Investigative Site Mainz 55131 Germany Details
Novartis Investigative Site Minden 32429 Germany Details
Novartis Investigative Site Ulm 89081 Germany Details
Novartis Investigative Site Budapest 1085 Hungary Details
Novartis Investigative Site Debrecen 4032 Hungary Details
Novartis Investigative Site Kaposvar 7400 Hungary Details
Novartis Investigative Site Mumbai Maharashtra 400012 India Details
Novartis Investigative Site Vellore Tamil Nadu 632 004 India Details
Novartis Investigative Site Nahariya 22100 Israel Details
Novartis Investigative Site Netanya 42150 Israel Details
Novartis Investigative Site Tel Aviv 6423906 Israel Details
Novartis Investigative Site Bologna BO 40138 Italy Details
Novartis Investigative Site Firenze FI 50134 Italy Details
Novartis Investigative Site Roma Lazio 00168 Italy Details
Novartis Investigative Site Milano MI 20122 Italy Details
Novartis Investigative Site Pavia PV 27100 Italy Details
Novartis Investigative Site Torino TO 10126 Italy Details
Novartis Investigative Site Varese VA 21100 Italy Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Seoul 03722 Korea, Republic of Details
Novartis Investigative Site Malaga Andalucia 29010 Spain Details
Novartis Investigative Site Salamanca Castilla Y Leon 37007 Spain Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Alicante Comunidad Valenciana 03010 Spain Details
Novartis Investigative Site La Coruna Galicia 15006 Spain Details
Novartis Investigative Site Las Palmas de Gran Canaria Las Palmas De G.C 35010 Spain Details
Novartis Investigative Site Pamplona Navarra 31008 Spain Details
Novartis Investigative Site Madrid 28034 Spain Details
Novartis Investigative Site Madrid 28046 Spain Details
Novartis Investigative Site Izmir 35040 Turkey Details
Novartis Investigative Site Talas / Kayseri 38039 Turkey Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field